Evaluation Of Clinical Safety And Tolerance Of A Lactobacillus Reuteri NCIMB 30242 Supplement Capsule: A Randomized Control Trial
| Effect |
Decrease |
| Trial Design |
Double blind |
| Trial Length |
1-6 months |
| Number of Subjects |
124 |
| Gender |
Both Genders |
| Age Range |
30-44, 45-64 |
| Body Types |
Overweight |
Notes for this study:
Supplementation of _l. reuteri_ NCIMB 30242 at 2.9x10^9^ CFU twice daily in otherwise healthy hypercholesteromic adults for nine weeks did not appear to confer any significant toxic effects relative to placebo.
LDL cholesterol appeared to be reduced 11.7% with supplementation, but most other parameters were unchanged.
Funding issues for this study:
Funding provided by Micropharma, producer of Cardioviva
Safety And Tolerance Of Lactobacillus Reuteri Supplementation To A Population Infected With The Human Immunodeficiency Virus
| Effect |
None |
| Trial Design |
Double blind |
| Trial Length |
2-4 Weeks |
| Number of Subjects |
39 |
| Gender |
Both Genders |
| Age Range |
18-29, 30-44, 45-64 |
| Body Types |
Average |
Notes for this study:
Supplementation of _l. reuteri_ at 10^10^ CFU in two divided doses a day for three weeks in persons with HIV failed to significantly influence any observed biochemical parameter to a level which was deemed practically relevant, with most parameters also failing to be significantly influenced.
Cholesterol Lowering And Inhibition Of Sterol Absorption By Lactobacillus Reuteri NCIMB 30242: A Randomized Controlled Trial
| Effect |
Decrease |
| Trial Design |
Double blind |
| Trial Length |
1-6 months |
| Number of Subjects |
127 |
| Gender |
Both Genders |
| Age Range |
30-44, 45-64 |
| Body Types |
Overweight |
Notes for this study:
_L. reuteri_ NCIMB 30242 in hypercholesterolemic adults over nine weeks at the dose of 2.9x10^9^ twice daily appeared to be able to reduce circulating LDL cholesterol (11.64%) and total cholesterol (9.14%) with an additional reduction of apolipoprotein B100 (8.41%) with no effect on HDL-C or triglycerides.
All benefits reported took six weeks, as there were no changes when reported at three weeks.
CRP and fibrinogen were also noted to be reduced with supplementation.
Funding issues for this study:
Conducted by researchers involved with Micropharma, producers of this particular strain
Cholesterol-lowering Efficacy Of A Microencapsulated Bile Salt Hydrolase-active Lactobacillus Reuteri NCIMB 30242 Yoghurt Formulation In Hypercholesterolaemic Adults
| Effect |
Decrease |
| Trial Design |
Double blind |
| Trial Length |
1-6 months |
| Number of Subjects |
114 |
| Gender |
Both Genders |
| Age Range |
30-44, 45-64 |
| Body Types |
Overweight |
Notes for this study:
_L. reuteri_ NCIMB at 5x10^9^ CFU daily for six weeks in persons with high cholesterol was able to moderately reduce both LDL cholesterol (8.92%) and total cholesterol (4.81%) with no influence on fecal bile acids nor other parameters of cardiovascular health.
Safety testing found supplementation to be well tolerated.
Funding issues for this study:
Some authors reported a potential conflict of interest as they are involved with the company which produces this strain (Micropharma limited)
